Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Sarcoma 3Sarcoma, Synovial 2Rhabdomyosarcoma 2Neurofibrosarcoma 2Liposarcoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Hemangiosarcoma 2Fibrosarcoma 2Triple Negative Breast Neoplasms 1Sarcoma, Alveolar Soft Part 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Malignant mesenchymal tumor 1Liposarcoma, Myxoid 1Hemangiopericytoma, Malignant 1Gastrointestinal Stromal Tumors 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Dexamethasone 110Cyclophosphamide 99Melphalan 91Bortezomib 68Peripheral Blood Stem Cell Transplantation 63Lenalidomide 57fludarabine phosphate 55Busulfan 53Filgrastim 50Antilymphocyte Serum 38Tacrolimus 37Thalidomide 36Radiotherapy 36Mycophenolic Acid 32fludarabine 28Cyclosporine 26Methotrexate 25Etoposide 22Calcium Dobesilate 22Prednisone 21Whole-Body Irradiation 20Methylprednisolone 20sargramostim 19pomalidomide 19Granulocyte Colony-Stimulating Factor 18carfilzomib 16daratumumab 15Cord Blood Stem Cell Transplantation 14Carmustine 14Rituximab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms, Plasma Cell × brostallicin × Clear all
NCT00060203 2014-01-16

Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma

Case Comprehensive Cancer Center

Phase 1/2 Completed
3 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡